Discovery and Nonclinical Development
The discovery of new products for patient use takes place in laboratories at universities, in the government, or in pharmaceutical companies; actually, it starts in the minds of scientists with a scientific innovation or idea for creating a new therapeutic molecule that may be a biological or drug. This research is performed through carefully done studies, either with the physiology of humans or other species, disease models, or some core structure of a molecule, through a host of different scientific technologies. Sometimes, a drug discovery is an accidental finding related to an unexpected action of a drug being studied for other uses, such as Viagra® for impotence. Each molecule may have an impact on a general physiologic process such as inflammation and thus have the potential to be used in many organ systems and diseases, or it may impact a specific receptor on a cell, such as a tyrosine kinase, and be used only when the receptor system goes awry. Knowledge of the discovery and early development process creates a basis for understanding how potential new therapeutics advance from the research laboratory to the clinic and some of the issues involved.
KeywordsDrug Discovery Biotech Company Drug Development Process Target Validation Target Discovery
Unable to display preview. Download preview PDF.
- 3.Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157(11):4986–4995.PubMedGoogle Scholar
- 4.Available at http://www.raptiva.com.
- 8.Available at www.scienceblog.com/community/older/2003/C/2003363.html.
- 9.Winslow R. The birth of a blockbuster: lipitor's route out of the lab. New York Times. January 24, 2000.Google Scholar
- 10.Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 2004;11(6):501–506.CrossRefPubMedGoogle Scholar
- 12.Lawrence CE. Acumen. J Sciences 2003;1:23.Google Scholar
- 16.Sachse C, Krausz E, Kronke A, Hannus M, Walsh A, Grabner A, Ovcharenko D, Dorris D, Trudel C, Sonnichsen B, Echeverri CJ. High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: Functional genomics investigations of biological pathways. Methods Enzymol 2005;392:242–277.CrossRefPubMedGoogle Scholar
- 17.Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173–178.CrossRefPubMedGoogle Scholar
- 24.Available at http://www.lipitor.com/Images/Lipitor/Lipitor_PI.pdf.
- 25.Available at http://www.epogen.com/pdf/epogen_pi.pdf.
- 31.Available at http://www.drugs.com/top200sales.html.
- 36.Available at http://www.fda.gov/cber/gdlns/ichs7a071201.htm.
- 38.Available at http://www.fda.gov/cber/gdlns/ind1.pdf.
- 39.Carroll SF. Development partnerships—accelerating product development through collaborative programs. BioProc Intl 2003:48–53.Google Scholar
- 40.King J. Today's drug discovery: unlocking greater potential. R&D Directions 2004, 10(2):28–39.Google Scholar
- 41.Ernst & Young. Resurgence: Global Biotechnology Report 2004.Google Scholar